Androgen Deprivation Therapy + Radiotherapy for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.
Who Is on the Research Team?
Michael Zelefsky, MD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for men with high-risk prostate cancer who have lower risk ARTERA scores. Participants should be healthy enough for hormone therapy and radiation, and not have conditions that would prevent them from completing treatment.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Androgen Deprivation Therapy (ADT)
- Radiotherapy
Trial Overview
The study tests if a short course (6 months) of hormone therapy (ADT) combined with higher-dose radiotherapy—including SBRT, possibly with brachytherapy—works well in these patients.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.